A sub-analysis of results from a multicenter, observational study shows that ceftolozane-tazobactam (C/T Zerbaxa, Merck) was well tolerated and effective in people living with cystic fibrosis (CF), even in those who may be allergic to penicillin. The findings offer a potential new antibiotic for this patient population (Open Forum Infect Dis 2024;11[8]:ofae391).
“While ceftolozane-tazobactam is not approved for use in people with cystic fibrosis exacerbations, it is